Landos Biopharma is a clinical-stage biopharmaceutical company focused on the development of oral therapeutics for patients with certain immunology diseases. Co.'s main candidate is NX-13, an oral, gut-selective NLRX1 agonist. In addition to NX-13, Co. has several preclinical product candidates: LABP-73, an oral, small molecule NLRX1 pathway agonist for the treatment of asthma and Chronic Obstructive Pulmonary Disease; LABP-66, an oral, small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis, and Alzheimer's disease; and LABP-69, an oral, small molecule PLXDC2 pathway agonist in development for the treatment of diabetic nephropathy and rheumatoid arthritis. The LABP average annual return since 2021 is shown above.
The Average Annual Return on the LABP average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LABP average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LABP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|